U.S. Markets closed

Moleculin Biotech, Inc. (MBRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.9200-0.1900 (-6.11%)
At close: 4:00PM EDT
3.0000 +0.08 (2.74%)
After hours: 04:55PM EDT
Sign in to post a message.
  • S
    up up..
  • L
    MBRX just went above the 30DMA @3.04. Maybe now the shorts will start to cover???
  • R
    loaded 40k shares long at 2.85, now we can reverse
  • S
    5 years of good cash runway.. this means likelihood of secondary offerings is low.
  • W
    Wish you luck!
    GO MBRX!
  • O
    One of few words
    Great stock to own...........if you have a 10 or 20 year horizon.....if not, sell the junk and move on.
  • S
    good news
  • A
    Last time I was checking this out I mentioned it was likely heading into the $3s and was roundly assaulted for making such a ridiculous statement. As usual I was right. Pretty decent price to load up now eh? Who wants to yell at me for starting to buy this now? lol
  • J

    HOUSTON, Dec. 1, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the US Food and Drug Administration (FDA) has approved its request for a "Rare Pediatric Disease" designation for its drug candidate WP1066. The designation entitles Moleculin to receive a transferrable Priority Review Voucher (PRV) upon New Drug Approval (NDA) for each of three indications, including diffuse intrinsic pontine glioma (DIPG), medulloblastoma and atypical teratoid rhabdoid tumor.
  • B
    HOUSTON, Feb. 2, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ:MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that a preclinical study in animals demonstrated a potentially significant therapeutic benefit of Annamycin against metastatic osteosarcoma. This appears to be the result of the high cytotoxic potential of Annamycin previously demonstrated in vitro against sarcoma cells in combination with its high uptake by the lungs where the tumors in this study are localized. Computerized tomography (CT) scans demonstrated that animals treated with Annamycin exhibited significant suppression of tumor growth and not a single death was observed in the treated animals, whereas significant tumor burden contributed to the rapid death of 90% of untreated animals. While the study continues, as of day 130, the survival rate for animals treated with Annamycin was 100%, compared with only 10% for untreated animals.
  • D
    I have to admit that MBRX has some credible collaborations.

    Emory University
    Moleculin entered into an agreement with Emory University to enable expanded cancer research on Moleculin’s WP1066 molecule for the possible treatment of medulloblastoma, a pediatric malignant primary brain tumor. Physician-scientists at Emory University and Children’s Healthcare of Atlanta have requested support to continue research aimed at the development of a novel treatment of medulloblastoma using WP1066 and Moleculin has agreed to supply them with a pure form of WP1066 for preclinical testing for the potential treatment of medulloblastoma. Emory studies so far have indicated that medulloblastoma may be particularly vulnerable to the ability of WP1066 to block the activated form of STAT3, a key signaling protein believed to contribute to the growth and survival of many tumors, including medulloblastoma.

    Mayo Clinic Research Endeavor
    Moleculin entered into an agreement with a physician at the Mayo Clinic to enable additional research on Moleculin’s WP1066 molecule for the possible treatment of a rare form of pediatric brain tumor. Mayo Clinic physician-scientists have requested and Moleculin has agreed to supply them with WP1066 for preclinical testing for the potential treatment of pediatric Diffuse Intrinsic Pontine Gliomas (DIPG), a rare and very aggressive form of brain tumor. Mayo Clinic studies have suggested that DIPG may be particularly sensitive to the inhibition of the activated form of a cell-signaling protein called STAT3, a primary target of WP1066, and their preliminary studies have demonstrated significant anti-tumor activity of WP1066 in DIPG in vitro and in vivo tumor models.

    The University of Iowa
    Moleculin entered into an agreement with The University of Iowa Pharmaceuticals for the development of a formulation for WP1732, a new molecule for cancer treatement. Based on preclinical testing, WP1732 is believed to be a breakthrough discovery and represents a major expansion of its STAT3 inhibition capability by providing a highly soluble alternative that is ideally suited for IV administration. This agreement marks the beginning of creating a preclinical package to submit to the FDA in order to request Investigational New Drug status.

    Medical University of Gdansk
    The Medical University of Gdańsk (MUG) is the largest medical university in northern Poland, located in one of the most beautiful cities in Europe with an old town and beautiful sandy beaches. The MUG educates nearly 6,000 undergraduate and postgraduate students at four Faculties: Faculty of Health Sciences, Faculty of Medicine, Faculty of Pharmacy and the Intercollegiate Faculty of Biotechnology. The MUG offers Premedical Course, Medicine Doctor Programme, Nursing Programme, Nutrition and Dietetics Programme and the Ph.D. Programmes, which are taught fully in English.

    University of Bergen
    Moleculin entered into an agreement to collaborate with the University of Bergen to expand research on inhibition of brain metastasis by Moleculin’s pre-clinical drug WP1066 and its unique ability to increase immune system response to cancer and suppression of tumor cell proliferation and survival.

    Additionally, Moleculin entered into a second collaborative agreement with the University of Bergen to test WP1122 in combination with the drug Avastin(R) (bevacizumab) made by Roche Pharma. Roche Pharma is not a party to the collaborative agreement.
  • M
    Cell culture model: Several drugs stop SARS-CoV-2 virus

    Frankfurt researchers discover starting points for COVID-19 therapy
    FRANKFURT. A team of biochemists and virologists from Goethe University and the University Clinic in Frankfurt has now been able to observe how the SARS-CoV-2 virus, the causative agent of COVID-19, changes human cells. The scientists tested a number of active substances in model tests in the laboratory, some of which slowed down or stopped the multiplication of the virus. These results make it possible to focus the search for an active ingredient on a small number of already approved drugs. (Nature DOI: 10.1038 / s41586-020-2332-7). Based on these results, a US company claims to be preparing an active ingredient for a clinical trial. A Canadian company is starting a clinical trial with another active ingredient.

    Since early February, Medical Virology at the University Hospital Frankfurt has had a cell culture model for the SARS-CoV-2 virus. From swabs from two infected returnees from Wuhan, the Frankfurt scientists led by Prof. Sandra Ciesek succeeded in growing the virus in an intestinal cell line (Hoehl et al. NEJM 2020). Using a technology developed at the Institute of Biochemistry II at the Goethe University Frankfurt, researchers from both institutes have now been able to show for the first time how the SARS-CoV-2 virus changes the host cell. The scientists used a special form of mass spectrometry, which they had only developed a few months ago, the so-called mePROD method. It can be used to determine the amount and production rate of thousands of proteins that are in the cell at a certain point in time.

    The results paint a picture of the course of a SARS-CoV-2 infection: While many viruses shut down their host's regular protein production in favor of viral proteins, SARS-CoV-2 has little effect on the protein production of the host cells - the viral proteins seem to compete with those Proteins of the host cell to be produced. Instead, the virus appears to increase the protein synthesis machinery. A weak point, the researchers suspected, and could actually significantly reduce the multiplication of the virus with inhibitors of protein production (translation inhibitors).

    24 hours after the infection, the virus causes marked changes in the composition of the host cell proteins: while the cholesterol metabolism is reduced, the activities in the carbohydrate metabolism and in the production of RNA for protein production increase. Accordingly, the scientists were able to successfully stop the virus multiplication in the cultivated cells with inhibitors against these processes. The use of an active ingredient that inhibits the production of new building blocks for viral genetics was similarly successful.

    The results have already made waves across the Atlantic: As usual since the beginning of the Corona crisis, the Frankfurt researchers have these immediately on a preprint server and on the website of the Institute of Biochemistry II ( https://www.biochem2.com / research-group / protein-quality-control # nav-coronavirus ). Prof. Ivan Dikic, Director of the Institute of Biochemistry II, comments: “Both the culture of 'open science', in which we share our scientific results as quickly as possible, and the interdisciplinary collaboration between biochemists and virologists have contributed to this success. The project started less than three months ago and is already revealing new therapeutic approaches for COVID-19. ”

    Prof. Sandra Ciesek, Director of the Institute for Medical Virology at the University Hospital Frankfurt, explains: “In a special situation like this, we also have to break new ground in research. The existing cooperation between the research groups of Prof. Jindrich Cinatl and Dr. Christian Münch from Virology and Biochemistry made it possible to quickly focus research on CoV-2. The results so far are a great confirmation of this interdisciplinary approach. ”

    The active substances that stopped the virus multiplication in the Frankfurt cell culture include 2-deoxy-D-glucose (2-DG), which intervenes directly in the carbohydrate metabolism necessary for the virus multiplication. The US company Moleculin Biotech has an active ingredient called WP1122, which is similar to 2-DG, a prodrug. Based on the results of the Frankfurt scientists, Moleculin Biotech says that it is already preparing this active ingredient for clinical studies: https://www.moleculin.com/covid-19/ .

    Based on another of the active ingredients tested in Frankfurt, ribavirin, the Canadian company Bausch Health Americas is now starting a clinical study with 50 subjects: https://clinicaltrials.gov/ct2/show/NCT04356677?term=04356677&draw=2&rank=1

    Dr. Christian Münch, head of the protein quality control group at the Institute of Biochemistry II and corresponding author, says: “Thanks to the mePROD technology we developed, we were able to follow the course of the virus infection in the la
  • K
    be honest. i'm new to researching this stock. my prediction website i use says this is a runner in the long term with price target range of $18 - 29 with a strong buy recommendation, but the negative side is the performance has underperformed and is rated a 2 0f 10. is this really something to get into right now and ride the wave back to 23.50? someone please that has invested in this already give me some friendly advice? was looking at call options and they are fairly cheap compared to other stocks. long call or just buy shares? opinions welcome
  • B
    I don't usually post on boards, but I noticed this article posted on Sterling Pharma Solutions website that it appears Moleculin has signed an agreement with Sterling to support the company's expanded development efforts for WP1122.

    Here's the article for your review.
  • T
    Thomas Nagurney
    Subject: Here's the science explaining MBRX's candidate WP1122:

    I am quoting from a source named: crawford2012 on Investorshub.com/MBRX

    Tackling Coronavirus with WP1122

    The Short Version
    Viruses (like SARS-CoV-2) depend on glycolysis and glycosylation for infectivity and replication.
    Glycolysis and glycosylation can be disrupted by using a glucose decoy known as 2-DG.
    And, while 2-DG has been shown to be effective in vitro, 2-DG’s lack of drug-like properties makes it ineffective as a drug in humans.
    WP1122 has the potential to solve 2-DG’s problem by creating a prodrug of 2-DG that reaches much higher tissue/organ concentrations than 2-DG alone.
    We are moving as quickly as possible to prepare WP1122 for clinical evaluation in the treatment of COVID-19.

    The Slightly Longer Version
    Moleculin (MBRX) has a unique opportunity to contribute to the global challenge posed by coronavirus and other viruses threatening our communities. We recently announced a collaboration with a major Texas university institution to evaluate our drug candidate, WP1122, and its analogs and this has now been followed by collaborations with additional players who bring the needed expertise to fully develop this new potential treatment for diseases like COVID-19.

    Independent researchers at the Institute of Biochemistry II – Goethe-Universität Frankfurt in Germany recently announced their discovery that 2-DG, the active compound in WP1122, reduced in vitro replication of SARS-CoV-2 by 100%.
    We now have a very strong reason to believe that WP1122 may be effective against COVID-19. This is based on the vital roles that glucose plays in the proliferation of SARS-CoV-2. Viruses like SARS-CoV-2 place increased demand on glucose and upregulate their host cell’s metabolic processes. Some of the most important of these processes are believed to be glycolysis and glycosylation.

    Understanding this is the key to understanding why WP1122 may represent a major breakthrough. Glycolysis and glycosylation sound similar, but they are very different, even though they rely on the same base material, glucose, which is essentially sugar. In highly simplified terms, glycolysis converts glucose into fuel and glycosylation uses glucose to help build important protein structures that enable the way our cells function with each other and respond to changes in their environment. When viruses like SARS-CoV-2 invade our cells, they coopt these processes to increase both their infectivity and their replication.

    How is everyone feeling about MBRX? From what I know, the company is doing very well with progress, development and seeking approval.

    I have a feeling something good or should I say very good is brewing and this is what we are reading all the recent news and moves the company is doing.

    I believe the WP1122 is going to kick butt and is going to stop Covid in its track 100%. The key is to stop the replication and so far, the science in the lab proved that, I am sure since then a lot of progress has been taking place behind the scene.
    Let's keep each other posted and updated. it's a win for all.
  • J
    The articles posted by Malcolm confirm what the company told us. Research was done in Germany. The researchers found some effectiveness in vitro. Goethe University has now published their research.

    No wrong doing by MBRX or it's management. My bet is the person/company that shorted 4 million shares in April was the entity that complained to the SEC to get them to halt the stock. That's called stock manipulation.
  • E
    Therapy inhibits key regulator of brain tumors while activating the immune response
    Therapy inhibits key regulator of brain tumors while activating the immune response
  • A
    Alex Lucas
    This will dip short term , but I'm an investor , not a speculator , long term it is still the same stock with a 3 dollar price target
  • M
    I asked investor relations for an update. This is what they said:

    I understand your frustration and the Company greatly appreciates your patience. The Company has responded to Nasdaq's inquiries and we are currently waiting for some additional feedback on their end. The process is ongoing, so I could not provide a tangible timeline, but I can assure you the company is working extremely hard at resolving the inquiries in as timely of a manner as they can. The Company will be sure to continue keep investors up to date on all additional updates that they are able to disclose.
  • L
    The patent deal with Houston's Medical Center MD Anderson is a milestone for Moleculin Biotech, Inc. How will the market interprets this achievement is yet to be seen. Good day ahead.